Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Randy Schmid who wrote (2583)	10/31/1997 12:14:00 PM
From: Izzy	Respond to of 6136

I have an article from "The AIDS Reader" [7(5):155-160, 1997], which I will briefly (hopefully accurately) paraphrase. It is anticipated that HIV patients will be placed in "managed care" programs. Most funding comes from federal Ryan White II, IIIb, and Medicaid. In Georgia, all FDA retroviral meds are provided. However, under the AIDS Drugs Distribution Program (ADDP), New Jersey, there is a variable drug formulary that has limited access to protease inhibitors. "But economic axioms declare that resources are finite, and dollar limits will ultimately be set against all patients for care." IMO, pure hypocrisy; why not give the best drugs?